Wave Life Sciences (WVE) Q4 results:
Revenues: $2.4M (-33.3%).
Net loss: ($56.8M) (-49.9%); loss/share: ($1.65) (-27.9%); Quick Assets: $147.2M (-15.8%).
32 mg data from both PRECISION-HD clinical trials are on track for H2.
Two additional CNS programs, SNP3 and C9orf72 are on track to initiate clinical development in H2.
Shares are down 12% premarket.
Previously: Wave Life Sciences EPS misses by $0.18, misses on revenue (March 2)
https://seekingalpha.com/news/3547351-wave-life-sciences-down-12-premarket-on-q4-miss
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.